OPXS · Optex Systems Holdings Inc

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.53 to $13.89 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.7600 to $14.3000 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0600 to $13.7500 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1850 to $13.7500 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0000 to $13.2700 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0050 to $13.2200 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.7550 to $14.2450 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0000 to $13.4650 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Each performance share represents a contingent right to receive one share of OPXS common stock. The performance shares vest in five equal increments, if, in each case and during a performance period beginning on December 18, 2025, the average VWAP per share of OPXS common stock over a 30 consecutive trading day period equals or exceeds a specified price.

Each performance share represents a contingent right to receive one share of OPXS common stock. The performance shares vest in five equal increments, if, in each case and during a performance period beginning on December 18, 2025, the average VWAP per share of OPXS common stock over a 30 consecutive trading day period equals or exceeds a specified price.

100% vesting on January 1, 2027. The NASDAQ closing price per share of common stock on the date of grant was $14.33

100% vesting on January 1, 2027. The NASDAQ closing price per share of common stock on the date of grant was $16.74.

100% vesting on January 1, 2027. The NASDAQ closing price per share of common stock on the date of grant was $16.74.

100% vesting on January 1, 2027. The NASDAQ closing price per share of common stock on the date of grant was $16.74.

This amendment is being filed to reflect that 2,965 of the 10,000 shares of common stock originally reported as granted to the reporting person were withheld on the transaction date reported to satisfy tax withholding obligations. As a result, a new row has been added to include transaction Code F, indicating the shares withheld for tax purposes. The reporting person's beneficial ownership in column 5 has been updated accordingly.

The reporting persons are (i) Topline Capital Management, LLC, an SEC registered adviser ("TCM"), and (ii) Collin McBirney, TCM's managing member.

Each reporting person may be deemed to beneficially own more than 10% of the issuer's outstanding shares of common stock. Each reporting person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of its or his pecuniary interest therein, and this report shall not be deemed to be an admission that any reporting person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.

The shares of common stock reported in Table I on this Form 4 are beneficially owned by Topline Capital Partners, LP, a Delaware limited partnership (the "Fund"). As a greater than 10% beneficial owner, the Fund is separately reporting its holdings in the issuer's securities on a Form 4 filed concurrently herewith. Each of TCM, as the investment manager and general partner of the Fund, and Mr. McBirney, as managing member of TCM, may be deemed to be the beneficial owner of the shares of common stock beneficially owned by the Fund.

The reporting persons are (i) Topline Capital Management, LLC, an SEC registered adviser ("TCM"), and (ii) Collin McBirney, TCM's managing member.

Each reporting person may be deemed to beneficially own more than 10% of the issuer's outstanding shares of common stock. Each reporting person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of its or his pecuniary interest therein, and this report shall not be deemed to be an admission that any reporting person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.

The shares of common stock reported in Table I on this Form 4 are beneficially owned by Topline Capital Partners, LP, a Delaware limited partnership (the "Fund"). As a greater than 10% beneficial owner, the Fund is separately reporting its holdings in the issuer's securities on a Form 4 filed concurrently herewith. Each of TCM, as the investment manager and general partner of the Fund, and Mr. McBirney, as managing member of TCM, may be deemed to be the beneficial owner of the shares of common stock beneficially owned by the Fund.

The reporting persons are (i) Topline Capital Management, LLC, an SEC registered adviser ("TCM"), and (ii) Collin McBirney, TCM's managing member.

Each reporting person may be deemed to beneficially own more than 10% of the issuer's outstanding shares of common stock. Each reporting person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of its or his pecuniary interest therein, and this report shall not be deemed to be an admission that any reporting person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.

The shares of common stock reported in Table I on this Form 4 are beneficially owned by Topline Capital Partners, LP, a Delaware limited partnership (the "Fund"). As a greater than 10% beneficial owner, the Fund is separately reporting its holdings in the issuer's securities on a Form 4 filed concurrently herewith. Each of TCM, as the investment manager and general partner of the Fund, and Mr. McBirney, as managing member of TCM, may be deemed to be the beneficial owner of the shares of common stock beneficially owned by the Fund.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2025.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2025.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2025.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2025.

The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2025.

The reporting persons are (i) Topline Capital Management, LLC, an SEC registered adviser ("TCM"), and (ii) Collin McBirney, TCM's managing member.

Each reporting person may be deemed to beneficially own more than 10% of the issuer's outstanding shares of common stock. Each reporting person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of its or his pecuniary interest therein, and this report shall not be deemed to be an admission that any reporting person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.

The shares of common stock reported in Table I on this Form 4 are beneficially owned by Topline Capital Partners, LP, a Delaware limited partnership (the "Fund"). As a greater than 10% beneficial owner, the Fund is separately reporting its holdings in the issuer's securities on a Form 4 filed concurrently herewith. Each of TCM, as the investment manager and general partner of the Fund, and Mr. McBirney, as managing member of TCM, may be deemed to be the beneficial owner of the shares of common stock beneficially owned by the Fund.

The reporting persons are (i) Topline Capital Management, LLC, an SEC registered adviser ("TCM"), and (ii) Collin McBirney, TCM's managing member.

Each reporting person may be deemed to beneficially own more than 10% of the issuer's outstanding shares of common stock. Each reporting person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of its or his pecuniary interest therein, and this report shall not be deemed to be an admission that any reporting person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.

The shares of common stock reported in Table I on this Form 4 are beneficially owned by Topline Capital Partners, LP, a Delaware limited partnership (the "Fund"). As a greater than 10% beneficial owner, the Fund is separately reporting its holdings in the issuer's securities on a Form 4 filed concurrently herewith. Each of TCM, as the investment manager and general partner of the Fund, and Mr. McBirney, as managing member of TCM, may be deemed to be the beneficial owner of the shares of common stock beneficially owned by the Fund.

100% vesting on January 1, 2026. The NASDAQ closing price per share of common stock on the date of grant was $8.10.

100% vesting on January 1, 2026. The NASDAQ closing price per share of common stock on the date of grant was $8.10.

100% vesting on January 1, 2026. The NASDAQ closing price per share of common stock on the date of grant was $8.10.

Each performance share represents a contingent right to receive one share of OPXS common stock. The performance shares vest in five equal increments if, in each case and during a performance period beginning on October 2, 2023, the average VWAP per share of OPXS common stock over a 30 consecutive trading day period equals or exceeds a specified price.

Each performance share represents a contingent right to receive one share of OPXS common stock. The performance shares vest in five equal increments if, in each case and during a performance period beginning on October 2, 2023, the average VWAP per share of OPXS common stock over a 30 consecutive trading day period equals or exceeds a specified price.

Each performance share represents a contingent right to receive one share of OPXS common stock. The performance shares vest in five equal increments if, in each case and during a performance period beginning on October 2, 2023, the average VWAP per share of OPXS common stock over a 30 consecutive trading day period equals or exceeds a specified price.

Each performance share represents a contingent right to receive one share of OPXS common stock. The performance shares vest in five equal increments if, in each case and during a performance period beginning on October 2, 2023, the average VWAP per share of OPXS common stock over a 30 consecutive trading day period equals or exceeds a specified price.